Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16

Benzinga Newsdesk www.benzinga.com Neutral 61.9%

Neg 0% Neu 61.9% Pos 0%

Jones Trading analyst Debanjana Chatterjee initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $16.